
Opinion|Videos|May 8, 2024
Innovations in Small Interfering RNA (siRNA) Therapy
Leading experts highlight the established role of PCSK9 inhibitors, such as evolocumab and alirocumab, and introduce the promising second-generation PCSK9 inhibitors, known as small interfering RNA (siRNA), which represent an innovative therapeutic approach that selectively reduces the production of specific proteins through RNA interference.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
FDA Approves Roflumilast 0.3% Cream for PsO in Children 2-5 Years
2
FDA Issues CRL for Oxylanthanum Carbonate in Hyperphosphatemia for CKD Patients on Dialysis
3
Functional Cures for T1D: Insulin Independence Through Islet Transplantation
4
Hypercortisolism as a Driver of Hypertension and Cardiovascular Risk
5

























































































